This feature highlights changes in clinical trial organizations’ personnel. 

Aethlon Medical

Charles Fisher has been named CEO of Aethlon Medical. Fisher currently serves as CEO of Margaux Biologics.

Agenus

Agenus has named Steven O’Day the company’s new chief medical officer. O’Day will continue to serve as executive director of the John Wayne Cancer Institute and Cancer Clinics at Providence St. John’s Health Center.

Almac Sciences

Almac Sciences has appointed Dan Bayston to the role of vice president of small-molecule active pharmaceutical ingredients. Bayston was formerly the company’s process development manager.

American Regent 

American Regent’s Ken Keller is transitioning from his current role as CEO of the company to global head of oncology business at Daiichi Sankyo. Paul Diolosa, American Regent’s current senior vice president of operations, will succeed Keller as president and CEO starting April 1, 2021.

AVITA Therapeutics

Sean Ekins, AVITA Therapeutics’ vice president of finance, assumed the role of chief financial officer at the company as of Nov. 9.

Avomeen

Avomeen has named Luke Miller as senior vice president of lab operations. Miller was formerly the vice president of lab operations at Metabolon.

Editas Medicine 

Lisa Michaels has been named chief medical officer of Editas Medicine. Michaels most recently served as head of Bayer Pharmaceuticals’ rare diseases, cell and gene therapy therapeutic area.

Elektrofi 

Boston-based Elektrofi has appointed Paul Herbert to the role of senior vice president of pharmaceutical development. Herbert most recently served as vice president of process development and engineering at Alkermes.

European Medicines Agency (EMA)

EMA Executive Director Guido Rasi has ended his five-year tenure as agency head, passing the reins to Emer Cooke, the current director of regulation and prequalification department at the World Health Organization, where she has served since 2016.

Graphite Bio

Katherine Vega Stultz has been appointed to chief operating officer of Graphite Bio. Formerly, Stultz was general manager of the Spain/Portugal market for Celgene. Graphite has also named Philip Gutry as the company’s chief business officer and head of finance and investor relations. Gutry was most recently chief business officer at Kronos Bio.

Illingworth Research Group

Chris Wells has been hired by Illingworth Research Group to serve as the company’s new director of patient concierge services. Previously, Wells was business development director of Activate Event Management.

Intravacc

Virgil Schijns has been appointed chief scientific officer of Intravacc. Schijns will continue to serve as guest professor at Strathclyde University in Glasgow, UK, a position he’s held since 2013.

Inventiva 

Clinical-stage biopharma company Inventiva has appointed Michael Cooreman to the role of chief medical officer. Cooreman most recently served as vice president of science and medicine at Ferring Pharmaceuticals.

Klick Health

Klick Health has named Lauren Naima, former FCB Health’s executive vice president and executive creative director, to the role of senior vice president and executive creative director in New York. Klick has also hired Laura Denham as the head of the company’s broadcast production team. Denham was previously the chief commercial officer at NotableCA. Ryan Murphy, who formerly served as senior vice president and creative director at the Grey Group, has joined Klick as group creative director.

Korro Bio 

Ram Aiyar has been named CEO of Korro Bio. Recently, Aiyar was the co-founder, chief financial officer and chief business officer at Corvidia Therapeutics.

Legend Biotech

Legend Biotech has named Ying Huang CEO of the company. Huang was managing director and head of biotech equity research at Bank of America Merrill Lynch prior to joining Legend Biotech.

Valicare

Christin Erbach has been named senior GMP consultant for Syntegeon subsidiary Valicare. She was most recently vice president of clinical services at Inceptua.

Werewolf Therapeutics 

Randi Isaacs, former executive director and clinical site head at NIBR, has been named chief medical officer of Werewolf Therapeutics.